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ABSTRACT
In patients with colorectal cancer (CRC), local and systemic inflammatory 
responses have been extensively reported to associate with cancer survival. However, 
the specific signalling pathways responsible for inflammatory responses are not clear. 
The PTEN/Akt pathway is a plausible candidate as it may play a role in mediating 
inflammation via COX-2, and has been associated with cancer progression. This study 
therefore examined the relationship between tumour PTEN/Akt/COX-2 expression, 
inflammatory responses and survival in CRC patients using a tissue microarray.
In 201 CRC patients, activation of tumour-specific PTEN/Akt significantly 
associated with poorer CSS (12.0yrs v 7.3yrs, P=0.032), poorer differentiation 
(P=0.032), venous invasion (P=0.008) and peritoneal involvement (P=0.004). 
Patients were stratified for peri-nuclear expression of COX-2 to examine associations 
with inflammatory responses. In patients with absent peri-nuclear COX-2 expression, 
activation of tumour-specific PTEN/Akt significantly associated with poorer CSS 
(11.9yrs v 5.4yrs, P=0.001), poorer differentiation (P=0.018), venous invasion 
(P=0.003) and peritoneal involvement (P=0.001). However, no associations were 
seen with either the local or systemic inflammatory responses.
In CRC patients, tumour-specific PTEN/Akt pathway activation was significantly 
associated with poorer CSS, particularly when peri-nuclear COX-2 expression was 
absent. However, activation of the PTEN/Akt pathway appears not to be responsible 
for the regulation of inflammatory responses.
INTRODUCTION
Colorectal cancer (CRC) is the second most common 
cause of cancer death in Europe [1]. Although outcomes 
have improved over the past decades, predominantly as a 
result of improvements in surgical technique and adjuvant/
neo-adjuvant therapies, survival still remains poor, with 
5-year survival of 50% across all stages of disease [2]. 
It is clear that the present TNM-based staging of CRC 
is suboptimal, with a need to identify characteristics 
pertaining to both the tumour and the host which may not 
only guide prognosis, but also novel adjuvant therapies.
Local and systemic inflammatory responses have 
been widely shown to play an active role in tumour 
development across a wide range of cancers including 
CRC [3–5]. This is now an area of intense research 
producing inflammatory-based scoring systems such as 
the Galon’s immunoscore [6], Klintrup-Makinen grade 
[7] or Glasgow Microenvironment score (GMS),[8] for 
local inflammation and the modified Glasgow prognostic 
score (mGPS) [9–11] or neutrophil-lymphocyte ratio 
(NLR) [12] for systemic inflammation, all of which 
have prognostic value independent of TNM staging [13]. 
However, the molecular pathways driving these local and 
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systemic inflammatory responses in CRC are not clear and 
establishment of the prognostic value of these pathways 
may provide novel therapeutic targets.
It has long been recognised that the prostaglandin 
pathway plays an important role when COX-2 is activated 
by inflammatory stimuli or CRC development. COX-2 
is the target for non-steroidal anti-inflammatory drugs 
(NSAIDs) and these are associated with beneficial 
treatment in patients with CRC. Cytoplasmic and 
peri-nuclear COX-2 can regulate the synthesis of 
prostaglandin E2 (PGE2), which is commonly upregulated 
in colon cancer [14]. PGE2 promotes inflammation via its 
receptors (EP1-4) to push T-cell differentiation towards 
a T-helper 1 (Th1) response, as is commonly seen within 
the CRC tumour microenvironment [15]. This suggests 
that COX-2 and PGE2 may play important roles in 
mediating the protective effects of the local inflammatory 
infiltrate within CRC patients. As well as regulating 
inflammation, COX-2 mediated synthesis of PGE2 has 
also been shown to regulate proliferation and migration 
of CRC cell lines [9, 16].
It has recently been delineated that the PTEN/Akt 
pathway can regulate expression of COX-2 and both 
phosphatase and tensin homolog (PTEN) and Akt are 
proposed to play an important role in cancer progression 
as well as inflammatory responses [17, 18]. For example, 
Akt can regulate migration of neutrophils, macrophages 
and CD8+ T-cells to the site of infection [19] and 
PTEN plays a role in suppressing Treg cell generation 
and function to remodel the tumour microenvironment 
[20–22]. This suggests that the PTEN/Akt pathway may 
regulate inflammatory responses via modulation of COX-2 
expression. The PTEN/Akt cascade has also been shown 
to be dysregulated in a variety of cancers [23–26].
However, the relationship between tumour 
PTEN/Akt/COX-2 expression and inflammatory 
responses in patients with CRC is not well defined, and 
most publications have focused on in vitro data [27]. 
Therefore, the aim of the present study was to examine 
the relationship between tumour PTEN/Akt/COX-
2 expression, inflammatory responses and survival in 
patients with CRC.
RESULTS
The PTEN/Akt pathway, cancer-specific survival 
and clinicopathological characteristics in CRC 
patients
A total of 201 patients, who underwent an elective, 
potentially curative resection of stage I-III CRC and had 
a valid score for all three assessed proteins were included 
in the study (Supplementary Table 1). Almost two thirds 
of patients were 65 or older at the time of surgery and 
just over half were male. Two thirds of patients underwent 
resection for colon cancer. Fourteen patients (7%) had 
pathological confirmation of stage I disease, whereas 
96 (48%) and 91 (45%) patients had stage II and stage 
III disease respectively. Twenty-seven patients (14%) 
had MMR deficient CRC, and fifty-six patients (28%) 
received adjuvant chemotherapy. The median follow-up 
of survivors was 11.2 years (range 6.2-16.0yrs) with 62 
cancer-associated deaths and 55 non-cancer deaths.
The histoscore for Akt473 phosphorylation ranged 
from 0-154 within the cytoplasm and from 0-24 at the 
membrane. PTEN expression ranged from 0-210 in the 
cytoplasm and 0-63 at the membrane (Supplementary 
Figure 1). Scores where split by the median into high and 
low expression for each protein at each cellular location. 
Neither cytoplasmic nor membrane Akt473 were associated 
with cancer-specific survival (CSS, Table 1). Similarly, 
neither cytoplasmic nor membrane PTEN were associated 
with CSS (Table 1).
Although neither cytoplasmic PTEN (cPTEN) 
expression (main location for PTEN inhibiting Akt 
activation) nor membrane Akt473 (mAkt473) phosphorylation 
(main location for Akt activation) was associated with 
CSS alone (Figure 1A, 1B), when considered together 
to make a cumulative prognostic score, were associated 
with CSS. cPTEN and mAkt473 were combined to make a 
cumulative prognostic score using two different models, 
1) simple model: High cPTEN/low mAkt473, both high, 
both low or low cPTEN/high mAkt473, and an off/on model 
of pathway activation: Off= High cPTEN/Low mAkt473 or 
High cPTEN/High mAkt473 or Low cPTEN/Low mAkt473 
and On= Low cPTEN/High mAkt473. The simple model 
did not associated with CSS (Figure 1C), however, the off/
on model was significantly associated with poorer CSS 
(12.0yrs v 7.3yrs, P=0.032 (HR 2.06), Figure 1D). The off/
on model was also associated with high risk pathological 
characteristics (Table 2), increased t-stage (P=0.030), 
poorer differentiation (P=0.032), venous invasion 
(P=0.008) and peritoneal involvement (P=0.004). No 
association with age, sex, site or inflammatory responses 
was observed.
The PTEN/Akt pathway, peri-nuclear COX-2 
and cancer-specific survival in CRC patients
As COX-2 is a potential downstream target of 
the PTEN/Akt pathway in cancer and has a role in 
inflammation, peri-nuclear tumour cell expression was 
assessed to investigate if COX-2 could provide a link 
between activation of tumour PTEN/Akt and inflammation. 
Peri-nuclear COX-2 (pnCOX-2) expression was assessed 
as absent or present (Supplementary Figure 1). When 
the off/on model was stratified by pnCOX-2 absence or 
presence; in patients with absent pnCOX-2 expression, 
the off/on model was associated with significantly poorer 
CSS (11.9yrs v 5.4yrs, P=0.001 (HR 3.04); Figure 2A). 
The 10yr-CSS rates were 69% and 33% for off and on, 
respectively (P=0.005, Table 1). In patients with pnCOX-2 
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Table 1: PTEN/Akt473/COX-2 expression and survival in patients undergoing elective, potentially curative resection 
of colorectal cancer (n=201)
 N (%) 10yr-CSS %
(SEa)
Univariate HRb
(95% CIc)
P
Cytoplasmic Akt473
 Low expression
 High expression
95 (47)
106 (53)
70 (5)
65 (5) 1.15 (0.70-1.89)
0.592
Membrane Akt473
 Low expression
 High expression
160 (80)
41 (20)
70 (4)
56 (9) 1.36 (0.76-2.45)
0.296
Cytoplasmic PTEN
 Low expression
 High expression
102 (51)
109 (49)
67 (5)
69 (5) 0.96 (0.58-1.58)
0.862
Membrane PTEN
 Low expression
 High expression
123 (61)
78 (39)
65 (5)
72 (6) 0.71 (0.41-1.20)
0.194
Combined cPTEN/
mAkt473 (simple model)
 High PTEN/Low  
Akt473
 High PTEN/High  
Akt473
 Low PTEN/ 
Low Akt473
 Low PTEN/High 
Akt473
77 (38)
83 (41)
22 (11)
19 (10)
69 (6)
71 (5)
60 (17)
47 (11)
1.14 (0.88-1.48) 0.159
Combined cPTEN/
mAkt473 (off/on model)
 All others (OFF)
 Low PTEN/High 
Akt473 (ON)
182 (90)
19 (10)
70 (4)
47 (11)
2.06 (1.05-4.07) 0.032
cPTEN/mAkt473 off/on 
model (No nuclear COX-
2; n=158)
 All others (OFF)
 Low PTEN/High 
Akt473 (ON)
142 (90)
15 (10)
69 (4)
33 (12)
3.04 (1.51-6.10) 0.001
cPTEN/mAkt473 off/on  
model (with nuclear 
COX-2; n=45)
 All others (OFF)
 Low PTEN/High 
Akt473 (ON)
40 (91)
4 (9)
72 (7)
100 (0)
0.42 (0.00-185.51) 0.251
a SE= Standard Error, b HR= Hazard Ratio, c CI= Confidence Interval.
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expression, there was no significant association of the off/
on model with CSS (11.9yrs v 16.0yrs, P=0.251 (HR 0.42), 
Figure 2B). The 10yr-CSS rates were 71% (off) and 100% 
(on) in these patients (P=0.222, Table 1).
The PTEN/Akt pathway, peri-nuclear COX-2 
and clinicopathological characteristics in CRC 
patients
It is only when pnCOX-2 expression is absent 
that the off/on model continues to associate with poorer 
CSS. In these patients, the off/on model is also more 
strongly associated with the high risk pathological 
characteristics (Table 2), increased t-stage (P=0.022), 
poorer differentiation (P=0.018), venous invasion 
(P=0.003) and peritoneal involvement (P=0.001). When 
patients are stratified for these factors, the off/on model is 
still significantly associated with poorer CSS in patients 
with moderate to well differentiation (12.2yrs v 5.3yrs, 
P<0.001, Figure 3A), venous invasion (7.5yrs v 3.7yrs, 
P=0.002, Figure 3B) and peritoneal involvement (10.2yrs 
v 4.0yrs, P=0.012, Figure 3C). However, no association 
was seen with either local or systemic inflammatory 
responses (Table 2).
Figure 1: Intra-tumour activation of the PTEN/Akt pathway is associated with cancer-specific survival in CRC 
patients. A. Kaplan Meier curve showing that in 201 CRC patients, cPTEN does not associate with CSS. B. Kaplan Meier curve showing 
that in 201 CRC patients, phosphorylation of mAkt473 does not associate with CSS. C. Kaplan Meier curves show that in 201 CRC patients, 
the simple model shows a slight trend towards poorer CSS. D. Whereas when cPTEN and mAkt473 were combined using the off/on model, 
there is a significant association with poorer CSS.
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Table 2: Relationship between cPTEN/mAKT473/nCOX-2 expression, clinicopathological characteristics and 
inflammatory responses in patients undergoing elective, potentially curative resection of colorectal cancer (n=201)
 
 
cPTEN/mAkt473 Absent nCOX-2
cPTEN/mAkt473
OFF
(n=182)
ON
(n=19)
P OFF
(n=142)
ON
(n=15)
P
Clinicopathological Characteristics       
Age
 <65
 >65
73 (40)
109 (60)
8 (42)
11 (58) 0.866
50 (35)
92 (65)
7 (47)
8 (53) 0.380
Sex
 Female
 Male
87 (48)
95 (52)
9 (47)
10 (53) 0.971
67 (47)
75 (53)
7 (47)
8 (53) 0.970
Adjuvant
 No
 Yes
132 (73)
50 (27)
13 (68)
6 (32) 0.704
105 (74)
37 (26)
10 (67)
5 (33) 0.545
Tumour site
 Colon
 Rectum
121 (66)
61 (34)
12 (63)
7 (37) 0.771
90 (63)
52 (37)
10 (67)
5 (33) 0.801
T stage
 1
 2
 3
 4
8 (4)
14 (8)
119 (65)
41 (23)
0 (0)
1 (6)
9 (47)
9 (47) 0.030
6 (4)
13 (10)
93 (65)
30 (21)
0 (0)
1 (7)
6 (40)
8 (53) 0.022
N stage
 1
 2
 3
103 (56)
63 (35)
16 (9)
7 (37)
10 (53)
2 (10) 0.174
80 (56)
51 (36)
11 (8)
5 (33)
8 (54)
2 (13) 0.103
Differentiation
 Mod/well
 Poor
164 (90)
18 (10)
14 (74)
5 (26) 0.032
131 (93)
11 (7)
11 (73)
4 (27) 0.018
Venous invasion
 Absent
 Present
123 (68)
59 (32)
7 (37)
12 (63) 0.008
94 (66)
48 (34)
4 (27)
11 (73) 0.003
Margin involvement
 No
 Yes
176 (97)
6 (3)
18 (95)
1 (5) 0.656
136 (96)
6 (4)
14 (94)
1 (6) 0.663
Peritoneal involvement
 No
 Yes
141 (77)
41 (23)
9 (47)
10 (53) 0.004
112 (79)
30 (21)
6 (40)
9 (60) 0.001
Mismatch repair status
 Competent
 Deficient
158 (87)
24 (13)
16 (84)
3 (16) 0.759
126 (89)
16 (11)
13 (87)
2 (13) 0.819
Proliferation Index
 Low
 High
67 (37)
115 (63)
5 (26)
14 (74) 0.362
51 (36)
91 (64)
5 (33)
10 (67) 0.855
Necrosis
 Low
 High
113 (62)
69 (38)
9 (47)
10 (53) 0.214
91 (64)
51 (36)
7 (47)
8 (53) 0.187
(Continued )
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cPTEN/mAkt473 Absent nCOX-2
cPTEN/mAkt473
OFF
(n=182)
ON
(n=19)
P OFF
(n=142)
ON
(n=15)
P
Tumour stroma percentage (n=182)
 Low
 High
130 (78)
36 (22)
10 (63)
6 (37) 0.152
105 (81)
24 (19)
8 (62)
5 (38) 0.091
Tumour Budding (n=186)
 No
 Yes
117 (69)
53 (31)
9 (56)
7 (44) 0.304
90 (68)
42 (32)
6 (46)
7 (54) 0.109
Inflammatory Characteristics       
Klintrup-Makinen grade
 Strong
 Weak
65 (36)
117 (64)
7 (37)
12 (63) 0.936
51 (36)
90 (64)
6 (40)
9 (60) 0.770
mGPS
 0
 1
 2
104 (57)
55 (30)
23 (13)
14 (74)
5 (26)
0 (0)
0.081
 
83 (58)
44 (31)
15 (11)
11 (73)
4 (27)
0 (0)
0.160
 
NPS (n=114)
 0
 1
 2
67 (68)
31 (31)
1 (1)
11 (73)
3 (20)
1 (7) 0.224
59 (70)
24 (29)
1 (1)
9 (69)
3 (23)
1 (8) 0.296
NLR (n=177)
 ≤ 5
 > 5
124 (78)
35 (22)
15 (83)
3 (17) 0.601
106 (84)
20 (16)
12 (86)
2 (14) 0.877
Figure 2: Peri-nuclear COX-2 stratifies CRC patients with an active intra-tumour PTEN/Akt pathway. A. Kaplan Meier 
curve showing that in 157 CRC patients with absent pnCOX-2 expression, the off/on model significantly associates with poorer CSS. B. 
Kaplan Meier curve showing that in 44 CRC patients with pnCOX-2 expression, the off/on model does not associate with CSS.
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Is the PTEN/Akt pathway an independent 
prognostic factor for CRC?
Since the off/on model had a significant association 
with poorer CSS in patients with absent pnCOX-2 
expression, this model was taken into univariate and 
multivariate analysis (Table 3). On univariate analysis, 
sex (P=0.014), TNM stage (P<0.001), venous invasion 
(P<0.001), margin involvement (P=0.005), peritoneal 
involvement (P=0.002), proliferation index (P=0.024), 
TSP (P<0.001), tumour budding (P<0.001) and KM Grade 
(P=0.005) were significantly associated with poorer CSS 
(Table 3).
On multivariate survival analysis including the 
off/on model; TNM stage (P=0.030), venous invasion 
(P=0.013), margin involvement (P=0.014), tumour 
budding (P=0.034) and KM Grade (P=0.008) were 
independent prognostic factors, with proliferation index 
(P=0.093) and TSP (P=0.094) showing trends towards 
independence (Table 3). However, the PTEN/Akt pathway 
does not appear to be independently prognostic in these 
patients (P=0.369).
DISCUSSION
The results of this study show that although the 
PTEN/Akt pathway is active in patients with CRC and 
is associated with poorer CSS, this pathway appears not 
to modulate local or systemic inflammatory responses. 
Indeed, the results of the present study suggest this 
pathway would be important within the tumour since 
it was associated with poorer differentiation, venous 
invasion and peritoneal involvement. Finally, this study 
confirms the importance of examining the PTEN/Akt 
pathway as a whole and not the individual components in 
isolation for patients with CRC.
The results within the present study are consistent 
with other studies that have suggested that activation of 
Akt can promote tumorigenesis by modulating tumour 
differentiation and invasion. Akt is a serine/threonine-
specific kinase with three isoforms, the ubiquitously 
expressed Akt1 and Akt2 plus the neuronal-specific 
Akt3. Akt1 is the most prominent and plays a role 
in many cellular processes which are important for 
cancer progression. Effects of Akt1 on differentiation 
and invasion are now starting to emerge in a variety of 
cancers. In CRC, in vitro studies have proposed that Akt1 
can inhibit cell growth and promote metastatic invasion 
by inducing epithelial to mesenchymal transition (EMT) 
[28, 29]. In the present study, there was a trend towards 
an association between tumour budding and patients 
with an active pathway. Tumour budding is suggested 
to be a marker for EMT. However, little other in vivo 
evidence exists to support this theory in CRC. There are, 
however, studies in patients with other cancers types. In 
prostate cancer patients, phosphorylated Akt1 is more 
highly expressed at the membrane of high grade, poorly 
differentiated tumours [30]. Akt1 has been shown to be 
an essential regulator of mammary cell differentiation in 
breast cancer via regulation of the STAT5 pathway [31]. 
Riggio et al. also showed that Akt1 regulates epithelial 
breast cancer differentiation via positive regulation 
of cytokeratin-8 and basement membrane formation. 
Furthermore, they suggested that Akt1 could affect tumour 
cell invasion via phosphorylation of focal adhesion kinase 
(FAK) [32]. The results of these studies propose an intra-
tumour role for activated Akt1 as an important regulator 
of tumour progression and metastasis.
Loss of PTEN is also hallmark of many cancers 
including CRC (particularly in MSI-CRC), causing hyper-
activation of the survival promoting Akt pathway and as 
this study shows poorer prognosis for patients [33–35]. 
In CRC patients, several groups have shown that loss of 
Figure 3: Intra-tumour activation of the PTEN/Akt/COX-2 pathway modulates CRC progression and invasive 
capacity. In patients with absent pnCOX-2 expression, the off/on model significantly associates with poorer CSS in patients with A. 
moderate to well differentiation, B. venous invasion and C. peritoneal involvement.
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Table 3: Univariate and multivariate survival analysis for patients with absent nCOX-2 expression undergoing 
elective, potentially curative resection of colorectal cancer (n=157)
 Univariate HRa
(95% CIb)
P Multivariate HRa
(95% CIb)
P
Clinicopathological Characteristics 
Age (<65/>65) 0.77 (0.44-1.35) 0.362 - -
Sex (Female/Male) 2.10 (1.16-3.80) 0.014 1.38 (0.69-2.84) 0.385
Adjuvant Therapy 
(No/Yes)
1.35 (0.75-2.45) 0.320 - -
Tumour Site (Colon/
Rectum)
1.19 (0.68-2.10) 0.546 - -
TNM Stage (1/2/3) 2.93 (1.71-5.02) <0.001 2.22 (1.08-4.53) 0.030
Differentiation 
(Moderate or well/
Poor)
2.22 (1.00-4.94) 0.051 - -
Venous Invasion 
(Absent/Present)
3.31 (1.86-5.89) <0.001 2.57 (1.22-5.38) 0.013
Margin Involvement 
(No/Yes)
3.76 (1.48-9.52) 0.005 3.56 (1.29-9.83) 0.014
Peritoneal 
Involvement (No/Yes)
2.44 (1.39-4.27) 0.002 1.02 (0.49-2.14) 0.958
Mismatch Repair 
Status (Competent/
Deficient)
0.84 (0.33-2.11) 0.705 - -
Proliferation Index 
(Low/High)
0.53 (0.30-0.92) 0.024 0.57 (0.30-1.10) 0.093
Necrosis (Low/High) 1.32 (0.75-2.33) 0.335 - -
Tumour Stroma 
Percentage 
(<50%/>50%)
3.68 (2.01-6.74) <0.001 1.92 (0.89-4.11) 0.094
Tumour Budding 
(No/Yes)
3.76 (2.05-6.88) <0.001 2.44 (1.07-5.55) 0.034
Inflammatory Characteristics 
Klintrup-Makinen 
Grade (Strong/Weak)
2.68 (1.34-5.36) 0.005 3.00 (1.34-6.73) 0.008
mGPS (0/1/2) 1.12 (0.74-1.70) 0.596 - -
NPS (0/1/2) 1.86 (0.95-3.64) 0.068 - -
NLR (<5/>5) 0.81 (0.32-2.06) 0.663 - -
PTEN/Akt Pathway 
cPTEN/mAKT473 
off/on model (OFF/
ON)
3.04 (1.51-6.10) 0.001 1.51 (0.62-3.69) 0.369
a HR= Hazard Ratio, b CI= Confidence Interval.
Oncotarget9www.impactjournals.com/oncotarget
PTEN correlates with local recurrence, advanced stage, 
lymph node metastasis and poorer CSS, suggesting a 
link between PTEN loss and an invasive CRC phenotype 
[36–38]. This invasive phenotype is also seen in vitro, 
where PTEN knock-down potentiates the invasiveness of 
HCT116 colorectal cancer spheroidal cells through a 3D 
extracellular matrix [39]. Similar effects are also seen in 
MKN-28 gastric cancer cells, where PTEN inhibits tumour 
cell growth and invasion via the downregulation of FAK 
expression [40].
However, within the present study associations 
with CSS, invasion and differentiation were only present 
when both Akt and PTEN are considered together. 
This is perhaps not unexpected as PTEN antagonizes 
phosphorylation of Akt when it resides in the cytoplasm 
and is therefore required to be downregulated in order for 
Akt to be activated [41]. Therefore, optimal activation 
of the pathway occurs when high Akt levels are present 
in the membrane and low PTEN levels are present in the 
cytoplasm, it is for this reason that these cellular locations 
were chosen for the models. This study also highlighted 
that looking at the whole pathway as active or inactive 
as for the off/on models is more relevant than simply 
combining low/high expression of the two proteins as 
done in the simple model. This study therefore proposes 
that looking at PTEN and Akt in isolation within CRC 
patients may not be the best approach and that considering 
the pathway as a whole may be crucial to understanding 
their function in this cancer.
Furthermore, the data indicates that the PTEN/
Akt pathway may be modulating pnCOX-2 expression 
to promote tumorigenesis. Since, the data does not 
reveal any associations with either local or systemic 
inflammatory responses; this suggests that pnCOX-2 has 
a role independent of inflammation in CRC. Furthermore, 
as it is patients with absent pnCOX-2 expression that have 
the worse prognosis, this proposes that pnCOX-2 can act 
as a tumour suppressor in CRC. It has been reported that 
COX-2 has a separate role as a transcription factor in the 
nucleus [42, 43] however the target genes for COX-2 have 
not been delineated. It has also been shown that COX-2 
may have tumour suppressive effects in mice where COX-
2 has been overexpressed or synthetic PGE2 administered 
[44, 45].
In conclusion, the results of this study show the 
PTEN/Akt pathway plays a role in CRC progression 
and is associated with a poorer prognosis for patients. 
However, this pathway appears not to be responsible for 
modulation of local or systemic inflammatory responses. 
The data does indorse that examining the pathway as 
a whole, such as with the off/on model may be more 
beneficial than looking at the individual components. The 
results from the off/on model suggest that the effects of 
the pathway are targeted to the tumour itself to modulate 
cancer progression by regulating pnCOX-2 expression to 
promote cellular differentiation and invasion. However, 
further work is still needed to fully understand the role of 
this pathway in CRC.
MATERIALS AND METHODS
Patients
Patients were identified from a prospectively 
collected and maintained database of CRC resections 
performed in a single surgical unit in Glasgow Royal 
Infirmary. For the present study, 201 patients who 
between 1997 and 2007 had undergone an elective, 
potentially curative resection for stage I-III CRC 
and were contained within a previously constructed 
tissue microarray (TMA) were included. Resection 
was considered curative on the basis of pre-operative 
computed tomography and intra-operative findings. 
Patients who received neoadjuvant therapy, or had 
died within 30 days of surgery were excluded. Ethical 
approval was obtained from the West of Scotland 
Research Ethics Committee.
Clinicopathological characteristics
Tumours were staged using the fifth edition of the 
AJCC/UICC-TNM staging system[46]. The presence 
of venous invasion was assessed using elastica staining. 
Following surgery, patients with stage III or high-risk 
stage II disease and without significant co-morbid disease 
precluding adjuvant treatment were considered for 
5-fluorouracil-based chemotherapy. Patients were followed 
up and date and cause of death were crosschecked with 
the cancer registration system and the Registrar General 
(Scotland). Cancer-specific survival (CSS) was measured 
from date of surgery until date of death from CRC.
The presence of tumour necrosis and tumour stroma 
percentage (TSP) were assessed as previously described 
[47]. Briefly using haematoxylin & eosin (H&E)-stained 
sections of the deepest point of invasion, necrosis was 
graded as either low-grade (focal or absent) or high-grade 
(moderate or extensive) and TSP was either graded as 
low (≤50%) or high (>50%). Mismatch repair (MMR) 
status was assessed as previously described [8]. Ki67 
proliferation index were previously established in this 
cohort.
The local inflammatory cell infiltrate was assessed 
using the Klintrup-Mäkinen (KM) grade as previously 
described [48]. Briefly, using full H&E sections of the 
deepest point of invasion, the inflammatory cell infiltrate 
at the invasive margin was graded as either low-grade (no 
increase or mild/patchy increase in inflammatory cells) or 
high-grade (prominent inflammatory reaction forming a 
band at the invasive margin, or florid cup-like infiltrate 
at the invasive edge with destruction of cancer cell 
islands). Neutrophil, platelet and lymphocyte counts were 
previously established in this cohort and used to generate 
Oncotarget10www.impactjournals.com/oncotarget
the neutrophil-platelet score (NPS) and neutrophil-
lymphocyte ratio (NLR).
Serum C-reactive protein (CRP) and albumin were 
recorded prospectively and measured within 30 days 
prior to surgery. The pre-operative systemic inflammatory 
response was defined using the modified Glasgow 
prognostic score (mGPS). The mGPS was calculated as 
previously described [13]; patients with CRP ≤10 mg/L 
were allocated a score of 0, patients with CRP >10 mg/L a 
score of 1, and patients with CRP >10 mg/L and albumin 
<35g/L were allocated a score of 2.
Immunohistochemistry
Immunohistochemical expression of PTEN, 
Akt473 and COX-2 was carried out using a previously 
constructed CRC TMA [49]. Sections were dewaxed in 
xylene then rehydrated using graded alcohols. Antigen 
retrieval for Akt473was performed using TE buffer pH9 
at 96°C for 20 minutes, PTEN in citrate buffer pH6 
under pressure for 5 minutes and COX-2 in TE buffer 
pH9 under pressure for 5 minutes before cooling for 20 
minutes. Endogenous peroxidase activity was blocked 
using 3% hydrogen peroxide for 10 minutes. 5% horse 
serum (PTEN/Akt473) or 20% goat serum (COX-2) was 
applied for 20 minutes at room temperature as a blocking 
solution. TMA sections were incubated overnight at 
4°C with primary AKT473or PTEN (Cell Signaling 
Technologies, US) antibody at a concentration of 4 ug/
ml and 1 ug/ml, respectively or for 2 hours at room 
temperature with primary COX-2 antibody (Abcam, 
UK) at 1:1000 dilution before washing the sections in 
TBS. Envision (Dako) was added to the sections for 30 
minutes at room temperature before washing in TBS. 
DAB substrate was added for five minutes until colour 
developed before washing in running water for ten 
minutes. Slides were then counterstained in haematoxylin 
for 60 seconds and blued with Scotts’ tap water before 
being dehydrated through a series of graded alcohols. 
Cover slips were applied using distrene, plasticizer, 
xylene (DPX).
Scoring
Stained TMA sections were scanned using a 
Hamamatsu NanoZoomer (Welwyn Garden City, 
Hertfordshire, UK) at x20 magnification and visualized on 
Slidepath Digital Image Hub (Leica Biosystems, Milton 
Keynes, UK). Assessment of Akt473and PTEN expression 
was performed by a single examiner (A.K.R) blinded to 
clinical data at x20 magnification (total magnification 
x400) using the weighted histoscore. The weighted 
histoscore is calculated as follows: 0x% not stained + 
1x% weakly stained + 2x% moderately stained + 3x% 
strongly stained. This gives a range of scores from 0 to 
300 and is calculated individually for membrane and 
cytoplasmic staining. As COX-2 was observed in the 
peri-nuclear region, a weighted histoscore could not be 
applied, therefore peri-nuclear COX-2 data was assessed 
by a single observer (L.B) and absence or presence of 
expression was noted. To ensure reproducibility, 10% of 
tumours were co-scored by a co-investigator (J.E.); the 
intraclass correlation coefficient was 0.960 for PTEN and 
0.882 for Akt473.
Statistical analysis
Only patients with a score for all three proteins 
were included in the analysis. Patients were divided 
into quartiles and the median (low/high) proven to be 
the most appropriate cut-off for analysis for PTEN and 
Akt473. The relationship between clinicopathological 
characteristics and protein expression was examined 
using the chi-square test for linear trend. The relationship 
between expression and CSS was examined using 
Kaplan-Meier method. The log rank test was utilized to 
compare significant differences between subset groups 
using univariate analysis. Multivariate cox regression 
analysis was performed to identify those factors that were 
independently associated with CSS. A P-value <0.05 was 
considered statistically significant. All analyses were 
performed using SPSS version 22.0 (IBM SPSS).
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